GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intensity Therapeutics Inc (NAS:INTS) » Definitions » ROIC %

Intensity Therapeutics (Intensity Therapeutics) ROIC % : -1,217.72% (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Intensity Therapeutics ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Intensity Therapeutics's annualized return on invested capital (ROIC %) for the quarter that ended in Mar. 2024 was -1,217.72%.

As of today (2024-05-24), Intensity Therapeutics's WACC % is 10.56%. Intensity Therapeutics's ROIC % is -253.11% (calculated using TTM income statement data). Intensity Therapeutics earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Intensity Therapeutics ROIC % Historical Data

The historical data trend for Intensity Therapeutics's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intensity Therapeutics ROIC % Chart

Intensity Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROIC %
-1,422.56 -1,002.09 -453.29 -201.79 -250.23

Intensity Therapeutics Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -105.36 -49.48 -128.67 -1,163.73 -1,217.72

Competitive Comparison of Intensity Therapeutics's ROIC %

For the Biotechnology subindustry, Intensity Therapeutics's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intensity Therapeutics's ROIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intensity Therapeutics's ROIC % distribution charts can be found below:

* The bar in red indicates where Intensity Therapeutics's ROIC % falls into.



Intensity Therapeutics ROIC % Calculation

Intensity Therapeutics's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROIC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=-8.319 * ( 1 - 0% )/( (4.798 + 1.851)/ 2 )
=-8.319/3.3245
=-250.23 %

where

Intensity Therapeutics's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Mar. 2024 is calculated as:

ROIC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=-18.972 * ( 1 - 0% )/( (1.851 + 1.265)/ 2 )
=-18.972/1.558
=-1,217.72 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Intensity Therapeutics  (NAS:INTS) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Intensity Therapeutics's WACC % is 10.56%. Intensity Therapeutics's ROIC % is -253.11% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Intensity Therapeutics ROIC % Related Terms

Thank you for viewing the detailed overview of Intensity Therapeutics's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Intensity Therapeutics (Intensity Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
61 Wilton Road, 3rd Floor, Westport, CT, USA, 06880
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors.
Executives
Emer Leahy director 1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH FL 33139
Daniel Donovan director 712 VISTA BLVD #305, WACONIA MN 55387
James M Ahlers officer: Executive VP of CF 2000 POWELL STREET, SUITE 1640, EMERYVILLE CA 94608
Lewis H Bender director, 10 percent owner, officer: President and CEO 765 OLD SAW MILL RIVER RD, TARRYTOWN NY 10591
Mark A Goldberg director PERCEPTIVE INFORMATICS INC, 200 WEST STREET, WALTHAM MA 02451
John M Wesolowski officer: Interim CFO 61 WILTON ROAD, 3RD FLOOR, WESTPORT CT 06880

Intensity Therapeutics (Intensity Therapeutics) Headlines

From GuruFocus